Upregulation of NUPR1 can be found in the ER+, estrogen-independent, tamoxifen-resistant breast cancer cells and high mRNA expression of NUPR1 correlates with poor clinical outcomes in ER+ endocrine therapy-treated breast cancer patients. This evidence concerns the gene ESR1 and breast carcinoma.